Characterizing the Mutational Landscape of In‐Transit Melanoma Metastases
Open Access
- 14 July 2026
- journal article
- research article
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (4) , e70112
Abstract
In‐transit melanoma (ITM) is a unique presentation of metastatic cutaneous melanoma associated with therapeutic challenges. Despite its clinical importance, the molecular drivers of ITM remain poorly defined. We aimed to characterize the mutational landscape of ITM and identify genetic alterations distinguishing it from other melanoma metastases. Tumor samples from 528 patients in the MSK‐IMPACT dataset, comprised of over 300 cancer‐related genes, were analyzed. Samples were classified as primary, in‐transit, regional lymph node, or distant metastases. Driver mutation frequencies were compared across groups, and mutual information (MI) and principal component analysis (PCA) were used to identify ITM‐associated genes and mutation patterns. NRAS Q61 mutations were enriched in ITM compared with other melanoma sites, while NF1 mutations were less common. Exploratory MI, PCA, and pairwise analyses identified recurrent NRAS MUT /wild‐type gene patterns that may distinguish ITM from other melanoma samples. Genes retained in the wild‐type state alongside NRAS MUT were associated with PI3K/AKT/mTOR, TGF‐β, and E2F‐related pathways. Collectively, these findings suggest that ITM is enriched for NRAS Q61 mutations and may have a comparatively lower co‐mutation burden, providing a basis for future studies of ITM biology and clinical behavior.Keywords
Funding Information
- National Institutes of Health (R01‐CA249229)
- National Cancer Institute (T32 CA163177)
- National Cancer Institute (CCSG P30CA044579‐32)
- National Center for Advancing Translational Sciences (UL1TR003015)
- National Center for Advancing Translational Sciences (KL2TR003016)
This publication has 19 references indexed in Scilit:
- Therapeutic Treatment Options for In-Transit Metastases from MelanomaCancers, 2024
- BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS‐mutant melanoma cells: Insights into mode of action and resistance mechanismsInternational Journal of Cancer, 2023
- The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort studyEuropean Journal of Cancer, 2022
- NRAS mutant melanoma: Towards better therapiesCancer Treatment Reviews, 2021
- In-transit metastatic cutaneous melanoma: current management and future directionsClinical & Experimental Metastasis, 2021
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapyNature, 2017
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivoProceedings of the National Academy of Sciences, 2013
- Parkin , a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27Proceedings of the National Academy of Sciences, 2003
- Molecular Clonality of In-Transit Melanoma MetastasisThe American Journal of Pathology, 2001